Why Bridge Warfarin to Apixaban?
You generally do NOT need to bridge warfarin to apixaban—bridging anticoagulation during the transition is not required in most patients. The FDA-approved transition protocol involves stopping warfarin and starting apixaban when the INR falls below 2.0, without any parenteral anticoagulation in between 1.
The Standard Transition Protocol
When switching from warfarin to apixaban, the process is straightforward:
- Stop warfarin completely
- Monitor INR until it drops below 2.0
- Start apixaban at that point (no bridging needed) 1
This approach works because:
- Apixaban reaches therapeutic levels rapidly (within hours of the first dose)
- There is no anticoagulation gap that requires filling with heparin or LMWH
- The overlapping anticoagulant effect as warfarin wears off and apixaban builds up provides continuous protection
When Bridging IS Used (The Exception)
Bridging with parenteral anticoagulation is only necessary when transitioning FROM apixaban TO warfarin, not the other way around 1. This is because:
- Warfarin takes several days to reach therapeutic effect
- The INR during early warfarin therapy is unreliable due to apixaban's residual effect on the INR 2
- A true anticoagulation gap exists during this transition
The FDA label explicitly states: "One approach is to discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range" 1.
Common Clinical Pitfall
The most important caveat: Do not confuse perioperative bridging (temporarily stopping anticoagulation for surgery) with transitioning between anticoagulants. These are completely different scenarios:
- Perioperative bridging = Using LMWH/heparin when stopping anticoagulation for surgery in high-risk patients 3
- Transitioning anticoagulants = Switching from one chronic anticoagulant to another
For perioperative management, apixaban should be stopped 24-48 hours before surgery depending on bleeding risk, and "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1.
Evidence Supporting No-Bridge Transition
Recent real-world data from 2023-2025 demonstrates that direct transitions from warfarin to apixaban are safe and effective 4, 5. In fact, switching from warfarin to apixaban was associated with reduced rates of the composite outcome of stroke, major bleeding, and death (rate ratio 0.92,95% CI 0.89-0.95) 5. The only notable risk increase occurs in the first 60 days after switching, which then attenuates—but this does not justify routine bridging, just careful monitoring 5.
Bottom line: The question itself reflects a common misconception. We don't bridge warfarin to apixaban because it's unnecessary and would only increase bleeding risk without reducing thrombotic risk.